Form 8-K - Current report:
SEC Accession No. 0000950170-22-002576
Filing Date
2022-03-01
Accepted
2022-03-01 17:10:01
Documents
14
Period of Report
2022-03-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20220301.htm   iXBRL 8-K 60189
2 EX-1.1 axsm-ex1_1.htm EX-1.1 492254
3 EX-5.1 axsm-ex5_1.htm EX-5.1 17198
  Complete submission text file 0000950170-22-002576.txt   761196

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20220301_lab.xml EX-101.LAB 12890
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20220301_pre.xml EX-101.PRE 9533
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20220301.xsd EX-101.SCH 2477
8 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20220301_htm.xml XML 4542
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 22699556
SIC: 2834 Pharmaceutical Preparations